Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701689 | Journal of Thoracic Oncology | 2017 | 21 Pages |
Abstract
This is the first study assessing the combination of EGFR and Janus kinase inhibition in patients with EGFR-mutant lung cancers. The combination was well tolerated but ineffective. Exosomal EGFR levels may reflect changes in tumor EGFR expression in response to therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Helena A. MD, Leslie BS, Qing PhD, Sizhi P. PhD, Mark G. MD, Gregory J. MD, PhD, Jacqueline MD, PhD,